JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knobelman, D. A.
Right arrow Articles by Lucki, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knobelman, D. A.
Right arrow Articles by Lucki, I.

Vol. 298, Issue 3, 1083-1091, September 2001

Genetic Regulation of Extracellular Serotonin by 5-Hydroxytryptamine1A and 5-Hydroxytryptamine1B Autoreceptors in Different Brain Regions of the Mouse

Deborah A. Knobelman, René Hen and Irwin Lucki

Departments of Pharmacology and Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania (D.A.K., I.L.); and Center for Neurobiology and Behavior, Columbia University, New York, New York (R.H.)

The regulation of extracellular levels of 5-hydroxytryptamine (serotonin) (5-HT) in the striatum and ventral hippocampus was studied using in vivo microdialysis in awake, unrestrained wild-type 5-HT1A and 5-HT1B receptor knockout mice. Systemic administration of the selective serotonin reuptake inhibitor fluoxetine evoked a significant dose-dependent increase in extracellular 5-HT in both the striatum and hippocampus at both 2.5 mg/kg (i.p.) and 20 mg/kg (i.p.) in wild-type mice. In 5-HT1A receptor knockout mice, the response to 2.5 mg/kg fluoxetine was significantly augmented in the striatum but not the hippocampus, whereas the response to 20 mg/kg fluoxetine was significantly greater in both brain regions. In 5-HT1B receptor knockout mice, the increase of extracellular 5-HT was augmented in the hippocampus but not the striatum at both doses of fluoxetine. The response pattern to fluoxetine alone in 5-HT receptor mutant mice corresponded with the effects of fluoxetine given with either the 5-HT1A receptor antagonist WAY 100635 (0.1 mg/kg i.p.) or the 5-HT1B/1D receptor antagonist GR 127935 (0.056 mg/kg) in wild-type mice. These results indicate common topographical regulation of 5-HT release in different brain regions by genetic mutation and pharmacological challenges. The 5-HT1A autoreceptor plays a larger role in regulating 5-HT release in the striatum and possibly other brain regions innervated by the dorsal raphe nucleus, whereas the role of the 5-HT1B receptor is relatively greater in the hippocampus and possibly other brain regions innervated by the median raphe nucleus.

0022-3565/01/2983-1083$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
B. P. Guiard, J.-P. Guilloux, C. Reperant, S. P. Hunt, M. Toth, and A. M. Gardier
Substance P Neurokinin 1 Receptor Activation within the Dorsal Raphe Nucleus Controls Serotonin Release in the Mouse Frontal Cortex
Mol. Pharmacol., December 1, 2007; 72(6): 1411 - 1418.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
A. Neumeister, X.-Z. Hu, D. A. Luckenbaugh, M. Schwarz, A. C. Nugent, O. Bonne, P. Herscovitch, D. Goldman, W. C. Drevets, and D. S. Charney
Differential Effects of 5-HTTLPR Genotypes on the Behavioral and Neural Responses to Tryptophan Depletion in Patients With Major Depression and Controls.
Arch Gen Psychiatry, September 1, 2006; 63(9): 978 - 986.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. F. Cryan, O. F. O'Leary, S.-H. Jin, J. C. Friedland, M. Ouyang, B. R. Hirsch, M. E. Page, A. Dalvi, S. A. Thomas, and I. Lucki
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors
PNAS, May 25, 2004; 101(21): 8186 - 8191.
[Abstract] [Full Text] [PDF]

Home page
 J Biol RhythmsHome page
P. J. Sollars, M. D. Ogilvie, M. A. Rea, and G. E. Pickard
5-HT1B Receptor Knockout Mice Exhibit an Enhanced Response to Constant Light
J Biol Rhythms, October 1, 2002; 17(5): 428 - 437.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. E. Page, J. F. Cryan, A. Sullivan, A. Dalvi, B. Saucy, D. R. Manning, and I. Lucki
Behavioral and Neurochemical Effects of 5-{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): A Combined Selective Inhibitor of Serotonin Reuptake and 5-Hydroxytryptamine1A Receptor Partial Agonist
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1220 - 1227.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. A. Knobelman, R. Hen, J. A. Blendy, and I. Lucki
Regional Patterns of Compensation following Genetic Deletion of Either 5-Hydroxytryptamine1A or 5-Hydroxytryptamine1B Receptor in the Mouse
J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1092 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. J. Mayorga, A. Dalvi, M. E. Page, S. Zimov-Levinson, R. Hen, and I. Lucki
Antidepressant-Like Behavioral Effects in 5-Hydroxytryptamine1A and 5-Hydroxytryptamine1B Receptor Mutant Mice
J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1101 - 1107.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.